ReviewBiomedicines2023
Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Habitual physical activity and sarcopenia: a systematic review and meta-analysis of prospective cohort studies.Journal of global health · 2026Pooled it
- Mapping the global landscape of behavioral interventions for sarcopenia in older adults: implications for clinical practice and research prioritization.BMC geriatrics · 2026Pooled it
- The potential of acupuncture in treating sarcopenia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2025Pooled it
- Gut microbial composition is altered in sarcopenia: A systematic review and meta-analysis of clinical studies.PloS one · 2024Pooled it
- Kimchi ProbioticJournal of microbiology and biotechnology · 2026Article
- Advances in electrical stimulation-based therapeutic technologies for sarcopenia prevention and treatment.Bioactive materials · 2026Review
- Altered Neuromuscular Control and Beta-Band Cortical Compensation During Gait in Sarcopenia: An Exploratory Study.Bioengineering (Basel, Switzerland) · 2026Article
- Bile Acid Metabolism Affects Muscle Regeneration in Aging Skeletal Muscle in a Manner Associated with Regulation of ABCB1 Expression.International journal of molecular sciences · 2026Article
- Hand grip strength and loss of independence in Indigenous and non-Indigenous New Zealand octogenarians-the LiLACS NZ cohort study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Dietary Preferences and Sarcopenia in Young and Middle-Aged Adults: A Population-Based Correlational Study.Nutrients · 2026Article
- Exploring neuronal mechanisms of osteosarcopenia in older adults.The Journal of physiology · 2026Review
- IL-6 signaling orchestrates proteolytic hubs MuRF1 and Atrogin-1 in NSCLC induced sarcopenia.Frontiers in immunology · 2026Article
- Myostatin inhibitors in sarcopenia treatment: A comprehensive review of mechanisms, efficacy and future directions.Molecular biology reports · 2025Review
- Therapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.JBMR plus · 2025Article
- Glucocorticoid-Mediated Skeletal Muscle Atrophy: Molecular Mechanisms and Potential Therapeutic Targets.International journal of molecular sciences · 2025Review
- Article
- Protective Efficacy ofInternational journal of molecular sciences · 2025Article
- Dietary advanced glycation end-products exacerbate sarcopenia onset by activating apoptosis through PRMT1-mediated CRTC3 arginine methylation.Cellular and molecular life sciences : CMLS · 2025Article
- Impact of Hospitalization on Sarcopenia, NADPH-Oxidase 2, Oxidative Stress, and Low-Grade Endotoxemia in Elderly Patients.Antioxidants (Basel, Switzerland) · 2025Article
- Effect and mechanism of miRNA-144-5p-regulated autophagy in older adults with Sarcopenia.Immunity & ageing : I & A · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare expenditure, sarcopenia in the elderly has become a major focus of research and public policy debates worldwide. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice, partly owing to the lack of available diagnostic testing and uniform diagnostic criteria. Since the World Health Organization and the United States assigned a disease code for sarcopenia in 2016, countries worldwide have assigned their own disease codes for sarcopenia. However, there are currently no approved pharmacological agents for the treatment of sarcopenia; therefore, interventions for sarcopenia primarily focus on physical therapy for muscle strengthening and gait training as well as adequate protein intake. In this review, we aimed to examine the latest information on the epidemiology, molecular mechanisms, interventions, and possible treatments with new drugs for sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.